About the Prix Galien Africa

The Prix Galien Africa rewards excellence and innovation. It is awarded for products, services and initiatives that are highly convincing or promising in the field of innovative discoveries and therapies for the benefit of humanity.

It is intended to reward researchers, institutions and pharmaceutical industries from the public or private sector that have developed initiatives, services, pharmaceutical, biotechnological, herbal medicine, diagnostic products and medical devices recently introduced on the African market.

In keeping with the spirit of the Prix Galien Africa’s mission, one special distinction may be awarded per edition. It may be proposed by the Jury to the Honorary Committee and whose criteria are defined by the Jury.

Pharmaceuticals, biotechnology, phytotherapy, diagnostics, medical devices and digital solutions must be based on innovative science, or developed through synthetic chemistry or molecular biology or made naturally with plants according to specific criteria, specifications, tested in controlled clinical trials and marketed by ethical pharmaceutical companies.

The product or device initial marketing authorization (MA) must be valid for a maximum of five years as of December 31 of the competition year.

Selection and Award

The Prix is open to researchers, institutions and pharmaceutical industries from the public or private sector, having developed pharmaceutical, biotechnological, herbal medicine, diagnostic products and medical devices, marketed in the countries of the African zone and having obtained Marketing Authorisation (MA), issued by at least one African pharmaceutical regulatory authority.

Pharmaceutical, biotechnology, phytotherapy, diagnostics and medical devices should be based on innovative science, developed through synthetic chemistry or molecular biology or made naturally from plants according to precise criteria, specifications, tested in controlled clinical trials and marketed by ethical pharmaceutical companies.

The product or device initial marketing authorization (MA) must be valid for a maximum of five years as of December 31 of the competition year.

The Prix Galien Africa rewards pharmaceutical sciences that improve the human condition, mainly on the basis of two criteria:

• Innovation and/or discovery
• Impact on the African continent

The following will not be taken into consideration

• Market dimension,
• the dimension of the company,
• development costs or distribution contingencies.

Depending on the results of the Jury’s evaluation of the entries, the Jury may decide not to award a category in a given year.

Applications may only be submitted electronically (by July 31, 2024 at 23:59 p.m (GMT) using the form available on this website.

Any questions can be sent by e-mail.